Phase I Study of Cobimetinib as a Single Agent or in Combination with other Anticancer Agents in Patients with Advanced Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2018
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2017 Planned number of patients changed from 12 to 42.
- 04 Oct 2017 Planned End Date changed from 1 Sep 2018 to 1 Apr 2019.